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Indeed, studies [2] [3] [4] [5] [6] [7] [8] have previously demonstrated that patients with more severe psoriasis are at an increased risk of cancer-related mortality, and psoriasis has been associated with an increased risk of cancer, including lymphoma. However, these studies have generally not controlled for important confounders, and have often failed to examine the rates of specific cancers or the impact of disease severity on cancer risk. Furthermore, there have often been conflicting data on the risk of specific cancers including lymphoma. 1, 3, 4, 6, 9 Additional studies are necessary to further define the risk of cancer in patients with this disease.
We performed a population-based cohort study using a nationwide, electronic medical records database from the United Kingdom to evaluate the association between psoriasis and cancer. In addition, our study also evaluated whether the risk of cancer in patients with psoriasis could be explained by a specific group of cancers and if this risk was higher in patients with more severe disease.
Methods
This study is a population-based cohort study analyzing data that had been collected prospectively since 2002 through January 2014 by general practitioners (GPs) in the United Kingdom who were unaware of the hypothesis being tested.
Data Source
Our source of data was The Health Improvement Network (THIN), an electronic medical records (EMR) database that contains anonymized medical record information from nearly 11.9 million patients across the United Kingdom. THIN has been extensively used for epidemiological research, and prior studies [10] [11] [12] [13] have validated the diagnostic accuracy of psoriasis and malignant disease codes used in THIN. Participants within THIN are considered to be representative of the general population of the United Kingdom in terms of their age, sex, geography, and medical diagnoses. 14 Information recorded includes patient demographics, medical diagnosis, and treatments prescribed, as well as referrals to specialists, hospitalizations, and laboratory results. THIN has the advantage over administrative claims databases (ie, Medicare) because it contains information on important risk factors for cancer, such as smoking, alcohol intake, and body mass index (BMI). 15 
Study Population
Our initial cohort within THIN consisted of all patients with a diagnosis of psoriasis and unexposed controls (ie, those with no recorded diagnosis of psoriasis). All patients with psoriasis who were ages 18 to 89 years at the start date and had observation time within THIN, after implementation of the EMR, were included. Patients were excluded if they died or transferred out of the practice prior to the implementation of EMR. Each patient with psoriasis was matched to up to 5 unexposed controls that were also 18 to 89 years at the start date and were from the same practice. Unexposed controls were assigned a "diagnosis" date based on having a recorded visit with the GP within 6 months (ie, ±180 days) of the corresponding patient's visit date to the GP. This algorithm was designed to minimize bias by ensuring that exposed patients and unexposed controls were followed by similar clinicians during similar time periods. Patients were initially excluded from the entire cohort if they had a personal history of any cancer, organ transplant, or human immunodeficiency virus (HIV) and/or AIDS, or had a diagnosis of hereditary diseases that have an increased susceptibility for developing malignant abnormalities, including albinism and xeroderma pigmentosum.
Protection of Study Subjects
This study was developed in accordance with the STROBE guidelines and was approved by the institutional review board of the University of Pennsylvania and by the Scientific Review Committee of CSD Medical Research, United Kingdom. This study was a population-based study using data already collected for these purposes. Data were collected by a third party and deidentified before they were made available for research purposes. Because our study analyzed data already collected for these purposes, patient consent was not required.
Definition of Exposure
Patients with psoriasis were identified by the presence of at least one diagnostic Read code for psoriasis in the patient's medical file. Read codes are a comprehensive numerical system developed in the United Kingdom to record diagnosis, symptoms, and tests, and is similar to the International Classification of Disease (ICD) codes. 16 The use of Read codes for modeling disease outcomes in patients with psoriasis has been previously validated in THIN. 13 Severity of psoriasis was classified as mild or moderate-to-severe depending on whether the patient was prescribed systemic therapy or phototherapy for psoriasis. Patients were classified as having moderate-tosevere psoriasis if they had ever received any prescription for psoralen, phototherapy, methotrexate, cyclosporine, acitretin, adalimumab, etanercept, infliximab, and/or ustekinumab. Patients were classified as having mild disease if they had never received treatment with any of these agents. This approach has been used in previous studies as a proxy for estimating disease severity.
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Person-Time Calculation
For exposed patients (ie, those who received at least 1 diagnostic code for psoriasis) the start of follow-up time occurred at the latest of the following: date of first diagnostic code for psoriasis in THIN; 180 days after patient registration with the practice; or when the practice began recording information using Vision software. For unexposed patients (ie, those with no diagnosis of psoriasis) the start time occurred at the latest of 3 dates: 180 days after patient registration, when the practice began recording information using Vision software, or the closest corresponding visit to the exposed patient's visit date
Outcome of Interest
The outcome of interest was incident cancer diagnosis. Cancer cases were identified using a series of Read codes selected a priori by the primary investigator (Z.C.C.F.). Patients were classified as having an incident cancer diagnosis if they received a code for any cancer (except carcinoma in situ or metastatic cancer) after the start date and on or before the end date of the study period. We also selected a priori specific cancer outcomes that were of interest to us, as part of secondary outcome analyses, either because prior studies have shown a possible association between psoriasis and risk of developing these malignant diseases or because they are considered important owing to public health implications.
Covariates
Covariates assessed in multivariable models as potential confounders included age, sex, BMI, smoking, and alcohol intake. Age and BMI were treated as continuous variables whereas smoking and alcohol intake were treated as categorical variables.
Sample Size
The sample size was fixed as we included all patients with a diagnosis of psoriasis in THIN who met our inclusion criteria. Using data on the incidence rates for all cancers, we would expect to detect a hazard ratio (HR) of 1.06 to 1.98 for patients with mild psoriasis and 2.02 to 7.79 for patients with severe disease for specific cancers assuming a 2-sided .05 significance level with a median follow-up period of 5 years and 80% power.
Analysis
Descriptive statistics were used to examine age, sex, disease severity, person-time, and covariate distribution among the cohort with exposed psoriasis and the control group. χ 2 Test was used to examine dichotomous variables. The nonparametric Wilcoxon-Mann-Whitney rank sum test was used to examine the continuous variables age and BMI. The rates of incident cancer diagnosis were descriptively reported as the cumulative incidence with 95% CIs for all cancers overall and stratified by cancer type in controls and patients with mild and severe psoriasis, separately. An unadjusted Cox proportional hazards model was then used to determine the HRs with 95% CIs for incident cancer diagnosis. The overall models were then adjusted for age and sex and were also adjusted for additional covariates using a purposeful selection modeling approach. 18 Covariates with biological plausible relationship to the exposure and outcome and those that resulted in a change in the point estimates of the main effects by more than 10% were kept in the final model. Multivariate models were examined for proportionality using diagnostic log-log plots. Finally, we performed multiple sensitivity analyses to test the underlying assumptions of our primary analysis. Statistical analyses were performed using STATA statistical software (version 13; Stata Corp).
Results
We identified 937 716 controls and 198 366 patients with psoriasis; 186 076 were classified as having mild psoriasis, and 12 290 were classified as having moderate-to-severe disease based on having received treatment with either phototherapy or systemic therapies (Table 1) . Overall, patients with psoriasis were younger, had higher BMI, and a greater proportion were male and current smokers compared with controls. In patients with moderate-to-severe disease, the most commonly prescribed systemic therapy was methotrexate (69.48%) ( Table 2) . The mean follow-up time across all outcomes varied from 6.39 to 6.57 years in the control group and 6.06 to 6.22 in the overall psoriasis group. The mean follow-up time in the mild and moderate-to-severe psoriasis group varied from 6.11 to 6.28 years, and 5.20 to 5.35 years, respectively. For all cancers, excluding NMSC, the number of new cancer cases identified was 32 241 in the control group and 6289 in the overall psoriasis group, of which 5490 were in the mild psoriasis group and 2186 in the moderate-to-severe psoriasis group. Unadjusted HRs with 95% CI showed that patients with moderate-to-severe psoriasis had a statistically significant higher risk of any lymphoma (HR, Table 3) .
The adjusted HR with 95% CI for specific cancer types are summarized in the Figure. Fully adjusted models showed a statistically significant increased risk for any cancer excluding NMSC, lymphoma, CTCL, lung cancer, and NMSC in patients with any psoriasis compared with controls, with this risk being higher in patients classified as having moderate-to-severe disease. A similar association was seen for any lymphoma, excluding CTCL, melanoma, and pancreatic cancer, where an increased risk was seen across all 3 groups; however, results were not statistically significant in the moderate-to-severe psoriasis group. In fully adjusted models, no statistically significant increased risk was observed across any of the groups for leukemia, breast, prostate, or colon cancer (Table 3) .
Results were robust to a number of sensitivity analyses ( Table 4) . Because smoking is an especially strong risk factor for lung cancer, we performed additional sensitivity analyses with the fully adjusted model limited to patients who were classified as never smokers. In this model, the association between psoriasis and lung cancer was lost in the overall (HR, 0.98; 95% CI, 0.76-1.25) and mild (HR, 0.97; 95% CI, 0.75-1.24) group and was decreased in the severe psoriasis group (HR, 1.18; 95% CI, 0.44-3.17). In contrast, an age-and sexadjusted model for lung cancer including only patients classified as current smokers showed a positive association between psoriasis and risk of lung cancer across all study groups.
Discussion
Prior studies evaluating the risk of cancer in patients with psoriasis have often shown conflicting results. Our results are consistent with those of a meta-analysis 1 that showed a small increased risk of cancer overall excluding NMSC (HR, 1.16; 95% CI, 1.07-1.25). As expected, we observed an increased risk for NMSC and lymphoma. In both instances, this risk was highest in patients with psoriasis who received systemic treatment or phototherapy. In patients defined as having moderateto-severe disease, the HR for incident NMSC was 1.61 (95% CI, 1.42-1.84). The risk for NMSC in patients with psoriasis has been previously described in the literature and has been primarily attributed to phototherapy exposure, particularly psoralen and ultraviolet A (PUVA). The risk for common solid organ malignant neoplasms, breast, colon, and prostate cancer was not higher than the general population. This finding suggests that positive associations seen for other internal malignant neoplasms, lymphoma, and lung cancer are not likely owing to screening bias. In our age-, sex-, and smoking-adjusted model, patients with moderate-to-severe psoriasis had an approximately 60% increased risk of developing lung cancer compared with patients without psoriasis (HR, 1.62; 95% CI, 1.16-2.28). Three prospective cohort studies [23] [24] [25] showed a positive association between psoriasis and lung cancer; however, models were not adjusted for smoking. In 2 prior studies in which adjustment for smoking was performed, one 8 found no positive association between psoriasis and lung cancer (incidence rate ratio [IRR], 0.79; 95% CI, 0.60-1.06), and the other 26 resulted in loss of the association when adjusting for this risk factor (HR, 1.3; 95% CI, 0.8-2.0). In additional sensitivity analyses, we showed a loss of this association when only including patients who were classified as never smokers. However, in models including only patients classified as former or current smokers, this association persisted. This observation would suggest that the relationship between smoking and lung cancer in patients with psoriasis is more complex. We found no clear association between psoriasis and either melanoma or pancreatic cancer. In the case of melanoma, psoriasis had a lower probability of developing melanoma when compared with a group of nondermatological patients. With respect to pancreatic cancer, a standardized incidence ratio (SIR) of 1.46 (95% CI, 1.10-1.95) has been previously reported, which is somewhat similar to our results (HR, 1.25; 95% CI, 1.04-1.51). 1 Interestingly, Brauchli et al 8 also found an increased incidence rate of pancreatic cancer in patients with psoriasis overall (HR, 2.20; 95% CI, 1.18-4.09). Our results showed a positive association across all study groups, yet we found no evidence of a dose-response effect with psoriasis severity. Chronic systemic inflammation, such as that seen in patients with severe psoriasis, has been postulated as a potential risk factor for pancreatic cancer. 28 Chronic alcohol consumption, which is reportedly higher in this population and often results in chronic pancreatitis, could be a contributing factor.
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Our study has certain strengths. We used a large, population-based database that has been used in similar epidemiological studies and contains information on wellestablished risk factors for cancer. We provide further evidence that the risk of cancer in patients with psoriasis, albeit small, applies to a specific group of cancers, including NMSC, lymphoma, and lung cancer. Nonetheless, our study has certain limitations. First, because THIN does not capture information on disease severity using physician-assessed measures, we used treatment exposure as a proxy for disease severity. This limited our ability to separate the effect of disease severity from the effect of treatment exposure on cancer risk. Second, the effect of biologic therapies on cancer risk cannot be properly assessed because the use of these medications is more restricted in the UK and therefore may not be readily captured within THIN. While data on the effect of treatment on cancer risk in patients with psoriasis are limited, studies [31] [32] [33] Finally, surveillance bias could have affected our results because patients with severe psoriasis might be followed more closely than their counterparts who do not have psoriasis or only have mild disease. We performed additional analyses limiting our entire cohort to patients seen at least once a year by their GP and observed similar results. In addition, if there was surveillance bias, we would have expected to see an increased risk of common cancers, such as breast, prostate, and colon cancer, and this was not observed. Care must be taken when interpreting our findings; in some cases our effects were small and could be related to chance because multiple outcomes were evaluated.
Conclusions
In conclusion, our data suggest that there is a small increased risk of cancer overall in patients with psoriasis. Patients with psoriasis who received treatment with systemic medications or phototherapy were shown to be at a higher risk for malignant neoplasms compared with controls. Future work should be aimed at developing a better understanding of the effect of disease severity and treatment exposure separately on cancer risk in this population. Dermatologists who care for patients with psoriasis should consider incorporating current cancer screening guidelines and counseling, such as smoking cessation, into their daily practice.
